06-05-01

PTO/SB/05 (2/98) Approved for use through 09/30/2000 OMB 0651-0032 , Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

ease type a plus sign (+) inside this box ->

The same

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No PC10795A First Named Inventor or Application Identifier THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS Title EL639817785US

Express Mail Label No APPLICATION ELEMENTS ADDRESS TO Box Patent Application See MPEP chapter 600 concerning utility patent application contents Washington, DC 20231 Microfiche Computer Program (Appendix) \*Fee Transmittal Form (e.g., PTO/SB/17) ibmīt an original, and a duplicate for fee processing) Nucleotide and/or Amino Acid Sequence Submission ITotal Pages 2 Specification 81 (if applicable, all necessary) (preferred arrangement set forth below) - Descriptive title of the Invention Computer Readable Copy - Cross References to Related Applications Paper Copy (identical to computer copy) h Statement Regarding Fed sponsored R&D Statement verifying identity of above copies Reference in Microfiche Appendix ACCOMPANYING APPLICATION PARTS - Background of the Invention Brief Summary of the Invention Assignment Papers (cover sheet & document(s)) Brief Description of the Drawings (if filed) 37 C F R. §3.73(b) Statement Power of Attorney Detailed Description Claim(s) (when there is an assignee) Abstract of the Disclosure English Translation Document (if applicable) 10. Copies of IDS Information Disclosure Drawing(s) (35 U.S.C. 11.3)[Total sheets Citations Statement (IDS)/PTO-1449 Oath or Declaration (Total pages 12. Preliminary Amendment Return Receipt Postcard (MPEP 503) 13 Newly executed (original or copy) (Should be specifically itemized) Copy from a prior application (37 CFR Statement filed in prior application, \*Small Entity §1.63(d)) (for continuation/divisional with Box 17 completed) Status still proper and desired Statement(s) [Note Box 5 below] (PTO/SB/09-12) DELETION OF INVENTOR(S) Certified Copy of Priority Document(s) 15 Signed statement attached deleting (if foreign priority is claimed) inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b). Other: Priority claim to U.S. Provisional patent Incorporation By Reference (useable if Box 4b is checked) 5. application no. 60/209,686 filed June 6, 2000, The entire disclosure of the prior application, from which a hereby incorporated by reference in its copy of the oath or declaration is supplied under Box 4b, is entirety. considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein. TEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO FAT SIMPLE FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCE IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28). If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment Continuation-in-part (CIP) of prior application No: / Continuation Divisional Group/Art Unit: Prior application information. Examiner CORRESPONDENCE ADDRESS 18 (Insert Customer No. or Attach bar code label here) Correspondence address below Customer Number or Bar Code Label Name Paul H. Ginsburg Address Pfizer Inc. 235 East 42nd Street, 20th Floor Address Zip Code 10017-5755 New York State New York City (212)573-1939 Fav United States Of America Telephone (212)573-2369 Country Registration No. (Attorney/Agent) 41.406 NAME (Print/type) Date Signature

PTO/SB/17/2/98

Approved for use through 09/30/2000 emark Office U.S. DEPARTMENT OF COMMERCE OMB 0651-0032 Patent and Trade Complete if Known FFF TRANSMITTAL Application Number Not Yet Assigned Herewith Filing Date Patent fees are subject to annual revision on October 1 First Named Inventor Luzzio et al These are the fees effective October 1, 1997 Not Yet Assigned Examiner Name Small Entity payments must be supported by a small entity statement. otherwise large entity fees must be paid. See Forms PTO/SB/09-12. Not Yet Assigned Group/Art Unit See 37 C F R. §§ 1 27 and 1.28. Total Amount of Payment (\$) 1574 PC10795A Attorney Docket No METHOD OF PAYMENT (check one FEE CALCULATION (continued The commissioner is hereby authorized to charge 3. ADDITIONAL FEES 1. 🖂 indicated fees and credit any over payments to: Large Entity Small Entity Deposit Fac Fee Fee Paid Fee Description 16-1445 Code Account Code (\$) (\$) Numbe Deposit 105 130 205 65 Surcharge - late fee or oath Account 127 50 227 25 Surcharge-late provisional filing fee or cover sheet Charge Any Additional Charge the Issue Fee Set in 37 C F.R. § 1 18 at the Mailing ed Under 139 130 130 130 Non-English specification 37 C.F.R. §§ 1.16 and 1.17 of the Notice of Allowance 147 2.520 147 2.520 For filing a request for reexamination 112 920 112 920\* Requesting publication of SIR pnor to Payment Enclosed: Examiner action 1.840\* Requesting publication of SIR after Check Money Order Other 1.840 113 Examiner action 1 25 FEE CALCULATION 55 Extension for reply within first month 115 110 215 1. BASIC FILING FEE Extension for reply within second 216 195 116 390 month 117 890 217 445 Extension for reply within third month Large Entity Entity Small Extension for reply within fourth month Fee Fee Description Fee Paid 118 218 695 1.390 Code (\$) Code (\$) 128 1.890 228 945 Extension for reply within fifth month 355 Utility filing fee 101= 710 201 110 310 210 155 Notice of Anneal 106 320 208 160 Design filing fee Filing a brief in support of an appeal 102 120 310 220 155 490 207 245 Plant filing fee 121 270 221 135 Request for oral hearing 108 710 208 355 Reissue filing fee 138 1.510 138 1.510 Petition to institute a public use Provisional filing fee 114 150 214 75 proceeding SUBTOTAL (1) (\$) 140 110 240 55 Petition to revive - unavoidable 2 EXTRA CLAIM FEES 241 620 Petition to revive - unintentional 141 1.240 1,240 Extra Fee from 142 242 620 Utility issue fee (or reissue) Fee Paid Cla 243 220 Design issue fee Total Claims 48 18 86/ 143 440 144 600 244 300 Plant seems foo 80 122 130 122 130 Petitions to the Commissioner Multiple Depende \*\* or number previously paid, if greater; For Reissues, see below 123 50 123 50 Petitions related to provisional Large Entity Small Entity applications Fee Description 128 240 126 240 Submission of Information Disclosure Code (\$) Code 15 Statement 103 18 203 Claims in excess of 20 581 40 581 40 Recording each patent assignment per property (times number of properties) 710 355 102 90 40 Independent claims in excess of 3 146 246 Filing a submission after final rejection (37 CFR 1 129(a)) 202 710 240 355 For each additional invention to be 104 270 204 135 Multiple dependent claim, if not paid 140 examined (37 CFR 1 129(b)) 109 80 209 40 \*\*Reissue independent claims over Other Fee (specify) original patent 110 18 210 "Reissue claims in excess of 20 and Other Fee (specify) over original patent SUBTOTAL (2) (\$) SUBTOTAL (3) (\$) \*Reduced by Basic Filing Fee Paid SUBMITTED BY Complete (if Applicable) Type or Printed Name Reg Number

Signature

Jue 4,200

Deposit Accoun

User ID